Searched for
ZYDUS BIOCHEM
Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...- Stock market update: Nifty Pharma index 0.02% in an upbeat marketThe Nifty Pharma index was trading 0.02 per cent at 21966.55.
- Stock market update: Nifty Pharma index falls 0.89% in a weak marketThe Nifty Pharma index was trading 0.89 per cent down at 20583.2.
- MNC pharma body OPPI appoints Anil Matai as new director generalThe Organisation of Pharmaceutical Producers of India (OPPI) has appointed Anil Matai as its director general. Matai has extensive experien...
- Stock market update: Nifty Pharma index falls 1.31%The Nifty Pharma index closed 1.31 per cent down at 11747.1.
- Stock market update: Nifty Pharma index falls 0.34% in a weak marketThe Nifty Pharma index was trading 0.34 per cent down at 11862.25.
- All Indian vaccines being developed for storage at 2-8 degree Celsius: DBT Secy"(For) all our vaccines, we are looking at right now...(we) are targeting 2-8 degree because our logistics are worked out on that basis and...
- Zydus Cadila in talks to sell two units for Rs 1,200 croreThis is part of a broader strategy to reduce debt in the company’s capital structure after it borrowed more to help finance the Rs 4,600-cr...
- Cadila set to buy US firm for $171 millionSentynl acquires, develops and commercialises prescription products, according to the company's website. It holds rights for opioid-based d...
- Flexi-jobs site Mykindofjob raises $1 million angel fundingMykindofjob.com, which says it has 800 companies on board, offers interactive web platform where registered users can communicate with each...
- Cadila Healthcare to acquire Claris Lifesciences for Rs 3,400 croreBoth sides are currently engaged in last-minute due diligence negotiations involving tax and other financial matters, said at least five so...
- Pharma sector sales growth slump in December quarter“India is an under-diagnosed market, so the argument that less people are falling sick might not be true,” asserts Sujay Shetty, head of li...
- Zydus Cadila in talks to buy Strides Arcolab' Rs 70-crore India generic businessZydus Cadila is in early stages of talks to acquire Bangalore-based Strides Arcolab's Rs 70-crore domestic generic business.
- Cadila Healthcare Q3 net dips by 4.4%, sales rise 20%Cadila Healthcare, the flagship company of Zydus group, has suffered a 4.4% drop in its third quarter net profit on account of forex losses.
- Daiichi Sankyo in buyout talks with 3 mid-sized companiesThe target firms of Daiichi Sankyo have a product portfolio straddling anti-diabetes, rheumatology and woman's healthcare.
- Zydus Cadila buys out Biochem PharmaceuticalsZydus Cadila has acquired 100% stake in Mumbai-based Biochem Pharmaceuticals for an undisclosed amount.
- Zydus Cadila acquires 100% stake Mumbai based BiochemBiochem has a presence in various therapeutic segments, including antibiotics, cardiovascular, anti-diabetics and oncology.
- Zydus Cadila in talks to acquire brands and manufacturing facility of Biochem PharmaceuticalsThe deal is expected to be valued at Rs 300-450 cr and will boost Biochem's revenue growth. In fiscal 2009-10, Biochem reported revenues of...
Load More
